These findings suggest that JAK2/STAT3/CCND2 signaling tends to be a resistance mechanism in CRC, offering potential biomarkers and therapeutic avenues for improving outcomes in CRC patients post-radiotherapy [116]. The gene discussed is CCND2; the disease is colorectal carcinoma.